The government needs to revise national guidelines to better target PrEP at those that would most benefit from it.
Eradicating a virus from the community requires everyone to have access to prevention, as is the case with tuberculosis. So why not HIV?
Blaming the rapid increases in syphilis cases on PrEP is an oversimplification of a complex problem.
World AIDS Day is Dec. 1. With many advances in preventing and treating the disease, the disease has fallen from top of mind for many. An epidemiologist explains why that could be dangerous.
Researchers from the BC Centre for Excellence in HIV/AIDS share the latest research on HIV prevention, treatment and stigma.
Modern factors are seeing a revival of the STI that was once consigned to history.
Doctors in South Africa performed a liver transplant from an HIV-positive donor to a HIV-negative recipient. Major ethical questions came into play.
Recently PrEP, an effective drug against HIV, was in the news with some concerns that gay men are no longer using condoms. But is the issue about condoms or control?
An increase in condomless sex in PrEP users is predictable as preventing HIV is the key motivator for condom use among gay and bisexual men.
Sharing data about users' HIV statuses is bad enough. But why collect it in the first place?
The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
HIV self-testing is a potential strategy to overcome access to testing. However, there are emerging concerns on the lack of counselling, possible user error and accuracy of the kits.
PrEP may be giving some homosexual and heterosexual users a false sense of security.
South Africa's data rollout of its pre-exposure prophylaxis shows that there is a relatively slow, but increasing, uptake. However, more needs to be done to target young women.
Stigma stops people from getting tested for HIV, and staying on their treatment. Unless it's addressed, the AIDS epidemic will persist.
Trials have shown that rates of HIV infection are reduced if people not infected with HIV take anti-retrovirals - known as pre-exposure prophylaxis (PrEP). But adherence to a daily dose is a problem.
Ignoring those at 'high risk' of HIV in order to sustain the idea of the 'good' gay man will only perpetuate the virus.
A judge has found that NHS England cannot reasonably refuse to fund anti-HIV drugs for gay men. This is a major step forward.
The focus of the 2016 International AIDS Conference has on access to necessary antiretrovirals, equity and making sure no-one is left behind. But there is a funding gap that needs to be addressed.
Thanks to treatment advances, people with HIV can and do live long and full lives. And that has led to a challenge that doctors and patients may not have imagined 35 years ago: the aging HIV patient.